Rebyota (Fecal Microbiota, Live-Jslm) Patent Expiration, LOE Window & CMS Spending
Rebyota (Fecal Microbiota, Live-Jslm) by Ferring Pharmac: Off-Patent Genericized (AB Competition), 0 AB generics, $1.9M 2024 CMS Part D & Medicaid spend, and $9,000 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Ferring Pharmac |
| FDA Application & Pathway | Reconciled (UNLINKED) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $1.9M |
| 2024 Medicare Part D Spend | $1.7M |
| 2024 Medicaid Spend | $230K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($9,000 intro WAC) |